AccueilInfos pratiques & communicationsBilans, rapports et recommandationsReport by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics

Report by the by the Access to Medicine Foundation: Pharma falls short on LMIC antibiotics

Partager l'article
Partager sur email
Partager sur twitter
Partager sur linkedin
Crédit : Pixabay

Article published on June 15, 2022 on Linksbridge.com

Pharma companies are overlooking opportunities to expand access to antibiotics in resource-limited settings, “resulting in significant gaps,” according to a report published last week by the Access to Medicine Foundation.

The document outlines 13 strategies for improving access, ranging from the “vital first step” of registering drugs in LMICs to technology transfers, product donations and more. A series of six case studies highlights tangible access initiatives from companies including Pfizer, Sanofi and Shionogi. 

The report also references market-nurturing incentives like the U.K.’s subscription purchase model.

On Wednesday, Britain’s National Health Service announced the rollout of the first drugs under that plan: Pfizer’s ceftazidime-avibactam and Shionogi’s cefiderocol (Fetroja).